Form 4: BeOne Medicines General Counsel Sells Shares for Tax Withholding

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, sold 920 American Depositary Shares for $304.6008 per share to cover tax withholding obligations related to a restricted share unit award.

Summary

• Lee Chan Henry, SVP, General Counsel of BeOne Medicines Ltd. (ONC), reported a transaction on July 30, 2025.
• 920 American Depositary Shares (ADS) were sold at a weighted average price of $304.6008 per ADS, with individual transaction prices ranging from $304.5725 to $304.605.
• The sale was executed to satisfy mandatory tax withholding requirements associated with the vesting of a previously granted restricted share unit (RSU) award.
• Each American Depositary Share represents 13 Ordinary Shares.
• Following this transaction, Lee Chan Henry beneficially owns 0 American Depositary Shares and 266,474 Ordinary Shares directly.
• The RSU award vests 1/4th annually on each anniversary of July 29, 2022, contingent on continued service, with accelerated vesting possible under certain termination events.

Sentiment

Score: 6

Explanation: The filing reports a mandatory sale of shares by an executive to cover tax obligations upon the vesting of restricted share units. This is a routine, non-discretionary transaction that reflects standard executive compensation practices and is generally considered neutral in sentiment, as it is not indicative of a discretionary sale or lack of confidence.

Positives

• The sale was non-discretionary, driven by mandatory tax withholding related to a restricted share unit award, which is a common and expected event for executives.
• The vesting of restricted share units indicates executive compensation and retention, aligning executive interests with company performance.

Negatives

• A portion of the executive's equity was sold, reducing their direct beneficial ownership of American Depositary Shares to zero.

Risks

• No specific risks beyond the standard operational risks inherent in executive compensation structures were detailed.

Future Outlook

The restricted share unit award is subject to continued service, with 1/4th vesting annually from July 29, 2022, indicating ongoing executive compensation and retention incentives.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.
• 1/4th of the securities will vest on each anniversary of July 29, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Industry Context

This transaction is a routine Form 4 filing, common for executives who receive equity compensation and are required to sell shares to cover tax obligations upon vesting. It reflects standard executive compensation practices within the industry.

Comparison to Industry Standards

• The sale for tax withholding purposes is a standard practice for executives receiving equity compensation across all industries, aligning with typical compensation structures seen in publicly traded companies. No specific comparable companies or projects are detailed in this filing.

Stakeholder Impact

• Shareholders: A minor, non-discretionary sale by an executive, which is a common occurrence and generally not indicative of a change in company outlook.
• Employees: The vesting of RSUs demonstrates the company's compensation structure for executives.

Next Steps

• Continued vesting of the remaining restricted share units on each anniversary of July 29, 2022, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a mandatory sale of shares by an executive to cover tax obligations related to the vesting of restricted stock units. Such transactions are routine and non-discretionary, not reflecting a change in the executive's confidence in the company or its future prospects. Therefore, this filing alone does not provide a basis for a change in investment recommendation; a 'Hold' stance is appropriate as it's a neutral event.

Keywords

BeOne Medicines, ONC, Form 4, insider transaction, executive compensation, stock sale, tax withholding, restricted stock units, RSU, American Depositary Shares, ADS